<Important Notes>
The forward-looking statements contained in this presentation are based on the Company’s assumptions and beliefs in the light of information currently available to it and involves known and unknown risks and uncertainties. Accordingly, there is a possibility that actual results and development programs may differ largely from these forecasts, due to a variety of factors. This report contains information on pharmaceutical products (including those under development), and the content of this report is not intended for medical promotion or medical advice. This translation is provided solely as a reference material. In the case of any discrepancy between the two versions, the original Japanese version shall prevail.
- April 25 2024 Personnel Changes of ASKA Pharmaceutical Holdings' Subsidiaries
- April 11 2024 ASKA Pharmaceutical Achieves the Primary Endpoint of Phase III Clinical Trial on LF111 in Japan
- April 1 2024 ASKA Pharmaceutical Initiates “Work Support Grant” Program and Cancer Insurance Program for All Regular Employees
- April 1 2024 Organizational and Personnel Changes of ASKA Pharmaceutical
For the previous news releases, please refer to the website of ASKA Pharmaceutical Holdings Co., Ltd.